Key Highlights
- First commercial sale for Multiply Labs’ robotic systems.
- Broad application in cell therapy, including CAR-T therapy manufacturing.
- Aims to enhance scalability, reduce costs, and accelerate therapy commercialization.
Source: Business Wire
Notable Quotes
- “The modular structure of the Multiply Labs robots will help enable Retro to bring its unique cell therapies to patients,” – Joe Betts-LaCroix, CEO at Retro Biosciences
- “This collaboration signifies a profound step forward in our efforts to harness cutting-edge robotic technology that helps patients access life-saving therapies,” – Fred Parietti, Ph.D., Co-founder and CEO at Multiply Labs
SoHC's Take
This partnership between Multiply Labs and Retro Biosciences is a significant milestone in the evolution of pharmaceutical manufacturing. By leveraging advanced robotics for the production of cell therapies, this collaboration not only underscores the potential for technological innovation to revolutionize treatment accessibility but also sets a new standard for the industry in manufacturing efficiency and scalability. The strategic utilization of automation to expedite the development and delivery of therapies will likely become a model for others in the biotech field, especially as they navigate the complexities of regulatory compliance and cost management. This agreement is a testament to the growing trend of integrating cutting-edge technologies in biopharmaceutical processes to meet the urgent healthcare needs of the global population.
